MODERNA WILL SEEK REGULATORY APPROVAL FOR THE COVID INFECTION FOR INFANTS

  • 23/03/2022

Moderna Inc said it will petition regulators to approve its Covid-19 vaccine in children under the age of six, citing findings from a clinical trial that showed it generated a similar immunological response to adults.

During Moderna's paediatric trial, the Omicron version of Covid-19 predominated, and the pharmaceutical reported that two doses were roughly 38% effective in preventing infections in children aged 2 to 5 years old and 44% effective in children aged 6 months to under 2 years old.

It claimed that these findings were consistent with the reduced efficiency of their vaccination against Omicron observed in individuals who had taken two doses. 

Moderna's vaccine might be the first approved shot for children under the age of five in the United States, and many parents of young children have been waiting for a vaccination for a long time.

A competing shot developed by Pfizer Inc and Germany's BioNTech SE is approved for use in children aged 5 and up. However, their trial results for 2- to 4-year-olds revealed a poorer immune response than in adults, necessitating an extension of the experiment to test a third dose. The findings are due in April.

Related News